Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06246630Recruiting
Personalized drug testing for advanced pancreatic neuroendocrine tumors
This trial uses a lab-grown model of your tumor (called an organoid) to test which drugs might work best for you. It is for people with advanced pancreatic neuroendocrine tumors who cannot have surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06195384RecruitingPhase 1
Personalized mRNA vaccine for advanced solid tumors
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
Guangzhou, GuangdongAges 18–75 - NCT06086522RecruitingPhase 1
Study of QN-302 for advanced solid tumors
This trial tests an experimental drug called QN-302 in people with advanced solid tumors that have grown despite standard treatments or for which no standard therapy exists. The goal is to see if it is safe and how the body processes it.
Scottsdale, ArizonaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT03723928Recruiting
Blood test–guided monitoring for metastatic breast cancer treatment
This study checks whether specific blood “tumor marker” levels can help monitor how hormone receptor–positive, HER2-negative metastatic breast cancer responds to first-line therapy. It uses regular blood tests (and sometimes scans) to see if this marker-based monitoring is useful and reliable.
Anchorage, AlaskaAges 18 years+ - NCT02555735Enrolling by invitation
Study of exceptional responders with solid tumors on chemotherapy
This study looks at people with solid tumor cancer (like many common carcinomas) to understand who responds exceptionally well to chemotherapy. You might be eligible if you are newly diagnosed or already receiving chemotherapy and can follow the study plan.
Los Angeles, CaliforniaAges 18 years+ - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT07751042RecruitingPhase 1/Phase 2
Study of STX-003 with and without pembrolizumab for advanced solid tumors
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05944224RecruitingPhase 1/Phase 2
SPH4336 for advanced solid tumors with or without immunotherapy
This early-phase study tests SPH4336 alone or combined with an immunotherapy drug called cadonilimab in people with advanced solid cancers that can’t be cured with surgery or local treatments. It aims to find out how safe it is and whether it can shrink tumors or control the disease.
Fuzhou, FujianAges 18–75 - NCT07127874RecruitingPhase 1
Study of PHN-012 for advanced solid tumors
This trial tests a new drug called PHN-012 for people with advanced colorectal, non-small cell lung, or pancreatic cancer who have already tried at least one standard treatment. The goal is to see if the drug can help shrink or slow tumor growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT05886920RecruitingPhase 1/Phase 2
Study drug for advanced cancers with specific MAPK changes
This Phase 1/2 study tests a new drug (D3S-002) to see if it can shrink or control advanced cancers that have certain MAPK pathway gene changes. It may help people whose cancer has progressed despite standard treatments, especially in a specific lung cancer group.
Detroit, MichiganAges 18 years+ - NCT07414836RecruitingPhase 1
First test of new drug BG-C0979 for advanced solid tumors
This study tests a new drug called BG-C0979 for advanced solid tumors that have not responded to standard treatments. It may be given alone or with other therapies to see if it can shrink tumors or slow cancer growth.
St Louis, MissouriAges 18 years+ - NCT07018960Recruiting
Chest wall repair with custom 3D-printed titanium implant
This study is testing a new way to repair large chest wall defects using a custom-made 3D-printed titanium implant. It may help people who need chest wall reconstruction after cancer surgery, a bad injury, or damage from infection or radiation.
Cruces, Basque CountryAges 18 years+ - NCT07070349RecruitingPhase 1/Phase 2
Study of HRS-6213 in healthy people and cancer patients
This trial tests a new drug called HRS-6213. It is first given to healthy volunteers to check safety, and then to patients with solid tumors to see if it can help treat their cancer.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06985368RecruitingPhase 1
Testing SIBP-A18 for advanced solid tumors
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
Beijing, Beijing MunicipalityAges 18–75 - NCT06981156Recruiting
Study of pediatric brain and spine tumor exams
This study tests a shorter way to check the brain and nervous system in children with brain or spine tumors. It aims to see if the new exam is as good as the standard one.
Madison, WisconsinAges 1–17 - NCT06969742Recruiting
Mental health program for young cancer survivors and caregivers
This trial tests a program to help improve mental health and quality of life for teenagers and young adults who have had a solid tumor cancer, and for their caregivers. It focuses on those recently finished treatment or still in treatment, and aims to provide supportive counseling.
Goyang-si, Gyonggi-doAges 10–24 - NCT06922487Recruiting
Tiredness study during awake brain tumor surgery
This trial looks at tiredness during awake brain surgery for tumor removal. It might help understand how awake procedures affect patients.
LundAges 18 years+ - NCT06992687Enrolling by invitationPhase 1/Phase 2
Study of HB0052 for advanced solid tumors
This trial tests a new drug called HB0052 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for various cancer types.
BeijingAges 18 years+ - NCT06894745RecruitingPhase 1
PET imaging of solid tumors with 89Zr-DFO-starPEG
This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06840288Recruiting
Lung tumor ablation registry study
This study tracks patients with small lung tumors that are treated with a robotic bronchoscope to destroy the tumor using heat. It aims to learn how well this procedure works over time.
Houston, TexasAges 18 years+ - NCT06844110Recruiting
New PET scan for cancer using CD73 probe
This trial tests a new PET imaging agent that targets CD73, a protein found on many cancer cells. It may help doctors see tumors more clearly without chemotherapy or radiation before the scan.
Dongcheng, Beijing MunicipalityAges 18–70 - NCT06859762RecruitingPhase 1
YL217 for advanced solid tumors (first-in-human)
This study tests a new drug, YL217, for people with advanced solid tumors. It is a first-in-human trial, meaning this drug has not been tested in people before, and aims to see if it is safe and how well it works.
Phoenix, ArizonaAges 18 years+
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,417 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.